NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer

[1]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[2]  H. Iwata,et al.  Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients , 2007, Breast Cancer Research.

[3]  Bharat B. Aggarwal,et al.  Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-κB, IκBα Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis* , 2006, Journal of Biological Chemistry.

[4]  N. Gueven,et al.  The complexity of p53 stabilization and activation , 2006, Cell Death and Differentiation.

[5]  D. Wallach,et al.  If the prophet does not come to the mountain: dynamics of signaling complexes in NF-kappaB activation. , 2006, Molecular cell.

[6]  Irene L Andrulis,et al.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.

[7]  J. Tschopp,et al.  Signals from within: the DNA-damage-induced NF-κB response , 2006, Cell Death and Differentiation.

[8]  R. Tibbetts,et al.  Molecular Linkage Between the Kinase ATM and NF-κB Signaling in Response to Genotoxic Stimuli , 2006, Science.

[9]  E. D. de Vries,et al.  Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors , 2006, Acta oncologica.

[10]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[11]  Gautam Sethi,et al.  Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. , 2006, The Journal of biological chemistry.

[12]  J. Tschopp,et al.  Signals from within: the DNA-damage-induced NF-kappaB response. , 2006, Cell death and differentiation.

[13]  P. Chumakov,et al.  The antioxidant function of the p53 tumor suppressor , 2005, Nature Medicine.

[14]  Päivi Heikkilä,et al.  Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival , 2005, Clinical Cancer Research.

[15]  C. Bolognesi,et al.  Biomarkers of exposure and effect in Bulgarian petrochemical workers exposed to benzene. , 2005, Chemico-biological interactions.

[16]  Y. Shaul,et al.  p53 Proteasomal Degradation: Poly-Ubiquitination is Not the Whole Story , 2005, Cell cycle.

[17]  M. Paquet,et al.  Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. , 2005, Cancer research.

[18]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[19]  C. Diaz-latoud,et al.  Cytotoxic effects induced by oxidative stress in cultured mammalian cells and protection provided by Hsp27 expression. , 2005, Methods.

[20]  Y. Shaul,et al.  Extra View p 53 Proteasomal Degradation Poly-Ubiquitination is Not the Whole Story , 2005 .

[21]  Farias Rogério Estevam,et al.  Apoptosis and production of TNF-α by tumor-associated inflammatory cells in histological grade III breast cancer , 2005, Cancer Immunology, Immunotherapy.

[22]  P. Nioi,et al.  Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. , 2004, Mutation research.

[23]  P. Souček,et al.  Breast cancer: role of polymorphisms in biotransformation enzymes , 2004, European Journal of Human Genetics.

[24]  X. Shu,et al.  Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. , 2004, Cancer Epidemiology, Biomarkers and Prevention.

[25]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[26]  L. Berliner,et al.  NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. , 2004, Molecular pharmacology.

[27]  P. Souček,et al.  Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations , 2004, British Journal of Cancer.

[28]  E. Yıldırım,et al.  Serum Levels of Tumor Necrosis Factor Alpha Correlate with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer , 2004, The International journal of biological markers.

[29]  David Siegel,et al.  Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* , 2003, The Journal of Biological Chemistry.

[30]  P. Nowell,et al.  Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. , 2002, Blood.

[31]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[32]  J. Lotem,et al.  Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Ponder,et al.  Effect of germ-line genetic variation on breast cancer survival in a population-based study. , 2002, Cancer research.

[34]  D. Labuda,et al.  Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Labuda,et al.  Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia , 2002, International journal of cancer.

[37]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Ross,et al.  Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. , 2001, Biochemical pharmacology.

[39]  D. Ross,et al.  Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. , 2001, Molecular pharmacology.

[40]  J. Lotem,et al.  Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Roop,et al.  NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. , 2000, Cancer research.

[42]  T. Naoe,et al.  Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  B. Butts,et al.  Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase. , 2000, Cancer research.

[44]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[45]  M F Greaves,et al.  A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. , 1999, Cancer research.

[46]  R. Larson,et al.  Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. , 1999, Blood.

[47]  D. Ross,et al.  Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. , 1999, Pharmacogenetics.

[48]  V Torri,et al.  Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[50]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[51]  R. Gelber,et al.  International Consensus Panel on the treatment of primary breast cancer. V: Update 1998. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[52]  D. Liebler,et al.  The Reduction of α-Tocopherolquinone by Human NAD(P)H:Quinone Oxidoreductase: The Role of α-Tocopherolhydroquinone as a Cellular Antioxidant , 1997 .

[53]  Xi,et al.  Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. , 1997, Cancer research.

[54]  D. Liebler,et al.  The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. , 1997, Molecular pharmacology.

[55]  M. Spitz,et al.  Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. , 1997, British Journal of Cancer.

[56]  L. Landi,et al.  The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Gelber,et al.  Meeting highlights: international consensus panel on the treatment of primary breast cancer. , 2002, Journal of the National Cancer Institute.

[58]  S. Ebbs,et al.  Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. , 1993, British Journal of Cancer.